Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids

Allergy and Asthma Proceedings

Volumn 33, Issue 3, 2012, Pages 258-264

  Hankin, Cheryl S ^a   Cox, Linda ^b   Lang, David ^c   Bronstone, Amy ^a   Wang, Zhaohui ^a   Lepore, Mark S ^d   Buck, Philip O ^d  

^a BioMed Econ LLC   (United States)

^b Nova Southeastern University   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON;

ADULT; AEROSOL; AGED; ALLERGIC RHINITIS; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AEROSOLS; AGED; CHILD; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL; YOUNG ADULT;

EID: 84862551618     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3565     Document Type: Article

References (40)

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
2. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 124:S43-S70, 2009.
3. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 30:244-254, 2009.
4. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
5. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 136:S107-S124, 2007.
6. Soni A. Allergic rhinitis: Trends in use and expenditures, 2000 to 2005. Statistical Brief 204. Bethesda, MD: Agency for Healthcare Research and Quality, 2008.
7. Meltzer EO, and Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106:S12-S16, 2011.
8. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 22:1203-1210, 2006.
9. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
10. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126:466-476, 2010.
11. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
12. Meltzer EO. The role of nasal corticosteroids in the treatment of rhinitis. Immunol Allergy Clin North Am 31:545-560, 2011.
13. Gross G, Jacobs RL, Woodworth TH, et al. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 89:56-62, 2002.
14. Storms WW. Introduction: Patient preference of inhaled nasal corticosteroids. Allergy Asthma Proc 22:S1-S3, 2001.
15. Kaliner MA. Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. Allergy Asthma Proc 22:S11-S15, 2001.
16. Small P, Houle PA, Day JH, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 100:592-595, 1997.
17. Shah SR, Miller C, Pethick N, et al. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 25:2198-2214, 2003.
18. Khanna P, and Shah A. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol 19:316-321, 2005.
19. Meltzer EO, Stahlman JE, Leflein J, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther 30:271-279, 2008.
20. Meltzer EO, Andrews C, Journeay GE, et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: A randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol 104:331-338, 2010.
21. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
22. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 93:345-350, 2004.
23. Meltzer EO, Bardelas J, Goldsobel A, et al. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med 4:289-296, 2005.
24. Bukstein D, Luskin AT, and Farrar JR. The reality of adherence to rhinitis treatment: Identifying and overcoming the barriers. Allergy Asthma Proc 32:265-271, 2011.
25. White P, Smith H, Baker N, et al. Symptom control in patients with hay fever in UK general practice: How well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 28:266-270, 1998.
26. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: A white paper. Allergy Asthma Proc 32:168-177, 2011.
27. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 98:12-21, 2007.
28. Naclerio RM, Hadley JA, Stoloff S, et al. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28(suppl 1):S11-S17, 2007.
29. Colthorpe P. Industry experiences of the HFA transition. Drug Delivery Syst Sci 3:41-43, 2003.
30. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs J Allergy Clin Immunol 121:227-232, 2008.
31. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: A large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 104:79-85, 2010.
32. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 172:1092-1097, 2010.
33. Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: Evidence and practice. Respir Med 104:615-625, 2010.
34. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 118:648-654, 1998.
35. Ciprandi G, Tosca M, Passalacqua G, et al. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 87: 222-226, 2001.
36. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62(suppl 85):9-16, 2007.
37. Ramirez LF, Urbinelli R, Allaert FA, et al. Combining H1- antihistamines and nasal corticosteroids to treat allergic rhinitis in general practice. Allergy 66:1501-1502, 2011.
38. Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:264-271, 2008.
39. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34:259-267, 2004.
40. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 62(suppl 85):17-25, 2007.